Bone Cancer Treatment Market By Type (Osteosarcoma, Chondrosarcoma, Ewing Sarcoma, Others), By Drug type (Immunotherapy and Targeted Therapy, Chemotherapy), By Distribution Channel (Hospital Pharmacies, Drug Store and Retail Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031

Bone Cancer Treatment Market

When a tumour, or abnormal mass of tissue, develops in a bone, it results in bone cancer. It appears when abnormal bone cells multiply uncontrollably. Bone tumors are typically benign (not cancerous). Mostly, benign tumors do not pose a threat to life and do not spread to other bodily regions. There are numerous treatment methods available depending on type of tumor, ranging from straightforward observation through tumor removal surgery.

Some bone tumors are malignant (cancerous). Malignant bone tumors can metastasize or cause cancer cells to spread throughout the body. In almost all cases, treatment for malignant tumors involves a combination of chemotherapy, radiation, and surgery. Chemotherapy, radiation therapy, and surgery are virtually always used in the management of malignant tumors. While they can develop at any age, they are more common in children, teenagers, and young adults than in older adults.

Major factors that drive growth of the market are increase in patient population of the bone cancer. Bone cancer is occurring in adults, children and teenagers as well. In addition, many government are taking initiatives to create awareness among people about bone cancer treatment and escalating demand for healthcare services is expected to majorly drive the market growth.

Furthermore, many organizations have invested in R&D activities to develop and launch new products. In past few years, there has been an increase in product innovation and product launch and are the leading bone cancer treatment market trends. Thus, increase in product launch is expected to flourish the market growth. Many organizations are signing agreement for efficient supply and manufacturing of bone cancer drugs. For instance, in August 2021 Cellectar Biosciences, Inc announced its agreement with Evergreen Theragnostic, it has entered into a commercial manufacturing and supply agreement with Evergreen to provide long term commercial supply of iopofosine I-131 and supply of clinical study material for Cellectar’s pivotal study in Waldenstrom’s macroglobulinemia (WM). The agreement adds second manufacturer and expands Cellectar’s current supply capabilities.

Surge in healthcare, industrial development, and investments from developed countries in Asia-Pacific, along with rise in awareness is anticipated to positively impact the bone cancer treatment industry during the forecast period. However high treatment and diagnostic costs associated with treatment of bone cancer is expected to hamper the bone cancer treatment industry growth.

By type, the bone cancer treatment market size is segmented into osteosarcoma, chondrosarcoma, Ewing sarcoma, and others. The osteosarcoma segment generated maximum revenue in 2021, and is expected to continue this trend throughout the forecast period, owing to increase in osteosarcoma cases and surge in product development for this type of cancer.

Depending on drug type, the bone cancer treatment market analysis is divided into immunotherapy & targeted therapy and chemotherapy. The immunotherapy & targeted therapy segment dominated the market in 2021, and is expected to continue this throughout the forecast period, owing to identification of molecular targets of cancer cells and less harmful effects on health.

Depending on distribution channel, the bone cancer treatment market size is divided into hospitals pharmacies, drug store & retail pharmacies, and online provider. The hospital pharmacies segment dominated the market in 2021, as they offer precise drug according to status of disease. The online provider segment is expected to witness highest CAGR during the forecast period, owing to increase in trend of online sales and related discounts

North America accounted for a majority of the global bone cancer treatment market share in 2021, and is anticipated to remain dominant during the forecast period. This is attributed to technological advancements in bone cancer treatment techniques and presence of key and robust hospital infrastructure in the region. However, Asia-Pacific is anticipated to witness notable growth, in bone cancer treatment market forecast owing to rise in bone cancer cases, development of healthcare infrastructure and increase in investment projects in the region.

 Key findings of the study

•    By type, the osteosarcoma segment was the highest contributor to the market in 2021.

•    By drug type, the immunotherapy & targeted therapy segment was the highest contributor to the market in 2021.

•    Depending on distribution channel, the hospital pharmacies segment was the highest contributor in 2021, and is expected to continue this trend during the forecast period.

•    Region wise, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.

Overview

 

The global bone cancer treatment market was valued at $1,182.54 million in 2021, and is estimated to reach $1,831.36 million by 2031, growing at a CAGR of 4.5% from 2022 to 2031. Bone cancer is one of numerous types of cancers that originates in the bones. It develops when abnormal cells proliferate uncontrollably in bone. It eradicates healthy bone tissues. Treatment for bone cancer includes immunotherapy, targeted therapies, chemotherapy, radiation therapy, and surgery.

Major factors that drive growth of the bone cancer treatment market is increase in government initiatives to create awareness for bone cancer treatment, rise in incidences of bone cancer, and surge in product launches and product approvals. In addition, increase in utilization for targeted therapies, personalization of medicines, and growth opportunities in emerging markets is a key trend of the market, which is expected to fuel growth during the the forecast period.

Significant surge in product launches and approvals is one of the leading factors of this market as product launch creates new opportunities to propel the market growth. For instance, in May 2021 CancerVax, Inc along with University of California Los Angeles (“UCLA”) to research and develop an immunotherapy breakthrough targeted at treating Ewing sarcoma. This is a rare but deadly soft tissue and bone cancer that primarily affects children and young adults.

In addition, various government organizations are taking initiatives to create awareness regarding the treatment of bone cancer. However high cost of drugs and diagnosis is expected to hinder growth of the market. Moreover, launch of various bone cancer treatment products to suffice consumer demands in developing countries is expected to provide a great opportunity for investors to invest in the market.

The global bone cancer treatment market is segmented on the basis of type, drug type, distribution channel, and region. On the basis of type, the market is categorized into osteosarcoma, chondrosarcoma, Ewing sarcoma and others. The Ewing sarcoma is further segmented on the basis of age group into below 45 and above 45. By drug type, it is divided into immunotherapy & targeted therapy and chemotherapy. By distribution channel, it is segmented into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America, the Middle East, and Africa (LAMEA).

The major players profiled in the report are Advaxis Inc., CancerVax, Inc, Cellectar Biosciences, Inc, Isofol Medical Ab, Pfizer Inc, Takeda Pharmaceutical Company Limited, Gradalis Inc. Hikma Pharmaceutical PLC, QSAM Biosciences, Inc., and Zentalis Pharmaceuticals.

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the bone cancer treatment market analysis from 2021 to 2031 to identify the prevailing bone cancer treatment market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the bone cancer treatment market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global bone cancer treatment market trends, key players, market segments, application areas, and market growth strategies.

 

Key Market Segments

○ Zentalis Pharmaceutical

Scope of Bone Cancer Treatment Market Report

1.1.Report description

1.2.Key market segments

1.3.Key benefits to the stakeholders

1.4.Research Methodology

1.4.1.Secondary research

1.4.2.Primary research

1.4.3.Analyst tools and models

2.1.Key findings of the study

2.2.CXO Perspective

3.1.Market definition and scope

3.2.Key findings

3.2.1.Top investment pockets

3.3.Porter’s five forces analysis

3.4.Top player positioning

3.5.Market dynamics

3.5.1.Drivers

3.5.2.Restraints

3.5.3.Opportunities

3.6.COVID-19 Impact Analysis on the market

4.1 Overview

4.1.1 Market size and forecast

4.2 Osteosarcoma

4.2.1 Key market trends, growth factors and opportunities

4.2.2 Market size and forecast, by region

4.2.3 Market analysis by country

4.3 Chondrosarcoma

4.3.1 Key market trends, growth factors and opportunities

4.3.2 Market size and forecast, by region

4.3.3 Market analysis by country

4.4 Ewing Sarcoma

4.4.1 Key market trends, growth factors and opportunities

4.4.2 Market size and forecast, by region

4.4.3 Market analysis by country

4.4.4 Ewing Sarcoma Bone Cancer Treatment Market by Age group

4.4.4.1 Below 45 Market size and forecast, by region

4.4.4.2 Above 45 Market size and forecast, by region

4.5 Others

4.5.1 Key market trends, growth factors and opportunities

4.5.2 Market size and forecast, by region

4.5.3 Market analysis by country

5.1 Overview

5.1.1 Market size and forecast

5.2 Immunotherapy and Targeted Therapy

5.2.1 Key market trends, growth factors and opportunities

5.2.2 Market size and forecast, by region

5.2.3 Market analysis by country

5.3 Chemotherapy

5.3.1 Key market trends, growth factors and opportunities

5.3.2 Market size and forecast, by region

5.3.3 Market analysis by country

6.1 Overview

6.1.1 Market size and forecast

6.2 Hospital Pharmacies

6.2.1 Key market trends, growth factors and opportunities

6.2.2 Market size and forecast, by region

6.2.3 Market analysis by country

6.3 Drug Store and Retail Pharmacies

6.3.1 Key market trends, growth factors and opportunities

6.3.2 Market size and forecast, by region

6.3.3 Market analysis by country

6.4 Online Pharmacies

6.4.1 Key market trends, growth factors and opportunities

6.4.2 Market size and forecast, by region

6.4.3 Market analysis by country

7.1 Overview

7.1.1 Market size and forecast

7.2 North America

7.2.1 Key trends and opportunities

7.2.2 North America Market size and forecast, by Type

7.2.2.1 North America Ewing Sarcoma Bone Cancer Treatment Market by Age group

7.2.3 North America Market size and forecast, by Drug type

7.2.4 North America Market size and forecast, by Distribution Channel

7.2.5 North America Market size and forecast, by country

7.2.5.1 U.S.

7.2.5.1.1 Market size and forecast, by Type

7.2.5.1.2 Market size and forecast, by Drug type

7.2.5.1.3 Market size and forecast, by Distribution Channel

7.2.5.2 Canada

7.2.5.2.1 Market size and forecast, by Type

7.2.5.2.2 Market size and forecast, by Drug type

7.2.5.2.3 Market size and forecast, by Distribution Channel

7.2.5.3 Mexico

7.2.5.3.1 Market size and forecast, by Type

7.2.5.3.2 Market size and forecast, by Drug type

7.2.5.3.3 Market size and forecast, by Distribution Channel

7.3 Europe

7.3.1 Key trends and opportunities

7.3.2 Europe Market size and forecast, by Type

7.3.2.1 Europe Ewing Sarcoma Bone Cancer Treatment Market by Age group

7.3.3 Europe Market size and forecast, by Drug type

7.3.4 Europe Market size and forecast, by Distribution Channel

7.3.5 Europe Market size and forecast, by country

7.3.5.1 Germany

7.3.5.1.1 Market size and forecast, by Type

7.3.5.1.2 Market size and forecast, by Drug type

7.3.5.1.3 Market size and forecast, by Distribution Channel

7.3.5.2 France

7.3.5.2.1 Market size and forecast, by Type

7.3.5.2.2 Market size and forecast, by Drug type

7.3.5.2.3 Market size and forecast, by Distribution Channel

7.3.5.3 UK

7.3.5.3.1 Market size and forecast, by Type

7.3.5.3.2 Market size and forecast, by Drug type

7.3.5.3.3 Market size and forecast, by Distribution Channel

7.3.5.4 Italy

7.3.5.4.1 Market size and forecast, by Type

7.3.5.4.2 Market size and forecast, by Drug type

7.3.5.4.3 Market size and forecast, by Distribution Channel

7.3.5.5 Spain

7.3.5.5.1 Market size and forecast, by Type

7.3.5.5.2 Market size and forecast, by Drug type

7.3.5.5.3 Market size and forecast, by Distribution Channel

7.3.5.6 Rest of Europe

7.3.5.6.1 Market size and forecast, by Type

7.3.5.6.2 Market size and forecast, by Drug type

7.3.5.6.3 Market size and forecast, by Distribution Channel

7.4 Asia-Pacific

7.4.1 Key trends and opportunities

7.4.2 Asia-Pacific Market size and forecast, by Type

7.4.2.1 Asia-Pacific Ewing Sarcoma Bone Cancer Treatment Market by Age group

7.4.3 Asia-Pacific Market size and forecast, by Drug type

7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel

7.4.5 Asia-Pacific Market size and forecast, by country

7.4.5.1 Japan

7.4.5.1.1 Market size and forecast, by Type

7.4.5.1.2 Market size and forecast, by Drug type

7.4.5.1.3 Market size and forecast, by Distribution Channel

7.4.5.2 China

7.4.5.2.1 Market size and forecast, by Type

7.4.5.2.2 Market size and forecast, by Drug type

7.4.5.2.3 Market size and forecast, by Distribution Channel

7.4.5.3 India

7.4.5.3.1 Market size and forecast, by Type

7.4.5.3.2 Market size and forecast, by Drug type

7.4.5.3.3 Market size and forecast, by Distribution Channel

7.4.5.4 Australia

7.4.5.4.1 Market size and forecast, by Type

7.4.5.4.2 Market size and forecast, by Drug type

7.4.5.4.3 Market size and forecast, by Distribution Channel

7.4.5.5 South Korea

7.4.5.5.1 Market size and forecast, by Type

7.4.5.5.2 Market size and forecast, by Drug type

7.4.5.5.3 Market size and forecast, by Distribution Channel

7.4.5.6 Rest of Asia-Pacific

7.4.5.6.1 Market size and forecast, by Type

7.4.5.6.2 Market size and forecast, by Drug type

7.4.5.6.3 Market size and forecast, by Distribution Channel

7.5 LAMEA

7.5.1 Key trends and opportunities

7.5.2 LAMEA Market size and forecast, by Type

7.5.2.1 LAMEA Ewing Sarcoma Bone Cancer Treatment Market by Age group

7.5.3 LAMEA Market size and forecast, by Drug type

7.5.4 LAMEA Market size and forecast, by Distribution Channel

7.5.5 LAMEA Market size and forecast, by country

7.5.5.1 Brazil

7.5.5.1.1 Market size and forecast, by Type

7.5.5.1.2 Market size and forecast, by Drug type

7.5.5.1.3 Market size and forecast, by Distribution Channel

7.5.5.2 Saudi Arabia

7.5.5.2.1 Market size and forecast, by Type

7.5.5.2.2 Market size and forecast, by Drug type

7.5.5.2.3 Market size and forecast, by Distribution Channel

7.5.5.3 South Africa

7.5.5.3.1 Market size and forecast, by Type

7.5.5.3.2 Market size and forecast, by Drug type

7.5.5.3.3 Market size and forecast, by Distribution Channel

7.5.5.4 Rest of LAMEA

7.5.5.4.1 Market size and forecast, by Type

7.5.5.4.2 Market size and forecast, by Drug type

7.5.5.4.3 Market size and forecast, by Distribution Channel

8.1. Introduction

8.2. Top winning strategies

8.3. Product Mapping of Top 10 Player

8.4. Competitive Dashboard

8.5. Competitive Heatmap

8.6. Key developments

9.1 Advaxis, Inc

9.1.1 Company overview

9.1.2 Company snapshot

9.1.3 Operating business segments

9.1.4 Product portfolio

9.1.5 Business performance

9.1.6 Key strategic moves and developments

9.2 Takeda Pharmaceutical Company Limited

9.2.1 Company overview

9.2.2 Company snapshot

9.2.3 Operating business segments

9.2.4 Product portfolio

9.2.5 Business performance

9.2.6 Key strategic moves and developments

9.3 Cancervax, Inc

9.3.1 Company overview

9.3.2 Company snapshot

9.3.3 Operating business segments

9.3.4 Product portfolio

9.3.5 Business performance

9.3.6 Key strategic moves and developments

9.4 Cellectar Biosciences, Inc

9.4.1 Company overview

9.4.2 Company snapshot

9.4.3 Operating business segments

9.4.4 Product portfolio

9.4.5 Business performance

9.4.6 Key strategic moves and developments

9.5 Pfizer, Inc

9.5.1 Company overview

9.5.2 Company snapshot

9.5.3 Operating business segments

9.5.4 Product portfolio

9.5.5 Business performance

9.5.6 Key strategic moves and developments

9.6 Isofol Medical Ab

9.6.1 Company overview

9.6.2 Company snapshot

9.6.3 Operating business segments

9.6.4 Product portfolio

9.6.5 Business performance

9.6.6 Key strategic moves and developments

9.7 Gradalis Inc

9.7.1 Company overview

9.7.2 Company snapshot

9.7.3 Operating business segments

9.7.4 Product portfolio

9.7.5 Business performance

9.7.6 Key strategic moves and developments

9.8 Hikma Pharmaceutical PLC

9.8.1 Company overview

9.8.2 Company snapshot

9.8.3 Operating business segments

9.8.4 Product portfolio

9.8.5 Business performance

9.8.6 Key strategic moves and developments

9.9 QSAM Biosciences, Inc.

9.9.1 Company overview

9.9.2 Company snapshot

9.9.3 Operating business segments

9.9.4 Product portfolio

9.9.5 Business performance

9.9.6 Key strategic moves and developments

9.10 Zentalis Pharmaceuticals

9.10.1 Company overview

9.10.2 Company snapshot

9.10.3 Operating business segments

9.10.4 Product portfolio

9.10.5 Business performance

9.10.6 Key strategic moves and development

LIST OF TABLES

TABLE 1. GLOBAL BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 2. BONE CANCER TREATMENT MARKET, FOR OSTEOSARCOMA, BY REGION, 2021-2031 ($MILLION)

TABLE 3. BONE CANCER TREATMENT MARKET FOR OSTEOSARCOMA, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 4. BONE CANCER TREATMENT MARKET, FOR CHONDROSARCOMA, BY REGION, 2021-2031 ($MILLION)

TABLE 5. BONE CANCER TREATMENT MARKET FOR CHONDROSARCOMA, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 6. BONE CANCER TREATMENT MARKET, FOR EWING SARCOMA, BY REGION, 2021-2031 ($MILLION)

TABLE 7. BONE CANCER TREATMENT MARKET FOR EWING SARCOMA, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 8. GLOBAL EWING SARCOMA BONE CANCER TREATMENT MARKET, BY AGE GROUP, 2021-2031 ($MILLION)

TABLE 9. BONE CANCER TREATMENT MARKET, FOR BELOW 45, BY REGION, 2021-2031 ($MILLION)

TABLE 10. BONE CANCER TREATMENT MARKET, FOR ABOVE 45, BY REGION, 2021-2031 ($MILLION)

TABLE 11. BONE CANCER TREATMENT MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)

TABLE 12. BONE CANCER TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 13. GLOBAL BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 14. BONE CANCER TREATMENT MARKET, FOR IMMUNOTHERAPY AND TARGETED THERAPY, BY REGION, 2021-2031 ($MILLION)

TABLE 15. BONE CANCER TREATMENT MARKET FOR IMMUNOTHERAPY AND TARGETED THERAPY, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 16. BONE CANCER TREATMENT MARKET, FOR CHEMOTHERAPY, BY REGION, 2021-2031 ($MILLION)

TABLE 17. BONE CANCER TREATMENT MARKET FOR CHEMOTHERAPY, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 18. GLOBAL BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 19. BONE CANCER TREATMENT MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)

TABLE 20. BONE CANCER TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 21. BONE CANCER TREATMENT MARKET, FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)

TABLE 22. BONE CANCER TREATMENT MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 23. BONE CANCER TREATMENT MARKET, FOR ONLINE PHARMACIES, BY REGION, 2021-2031 ($MILLION)

TABLE 24. BONE CANCER TREATMENT MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 25. BONE CANCER TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)

TABLE 26. NORTH AMERICA BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 27. NORTH AMERICA EWING SARCOMA BONE CANCER TREATMENT MARKET, BY AGE GROUP, 2021-2031 ($MILLION)

TABLE 28. NORTH AMERICA BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 29. NORTH AMERICA BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 30. NORTH AMERICA BONE CANCER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 31. U.S. BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 32. U.S. BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 33. U.S. BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 34. CANADA BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 35. CANADA BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 36. CANADA BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 37. MEXICO BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 38. MEXICO BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 39. MEXICO BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 40. EUROPE BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 41. EUROPE EWING SARCOMA BONE CANCER TREATMENT MARKET, BY AGE GROUP, 2021-2031 ($MILLION)

TABLE 42. EUROPE BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 43. EUROPE BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 44. EUROPE BONE CANCER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 45. GERMANY BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 46. GERMANY BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 47. GERMANY BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 48. FRANCE BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 49. FRANCE BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 50. FRANCE BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 51. UK BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 52. UK BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 53. UK BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 54. ITALY BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 55. ITALY BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 56. ITALY BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 57. SPAIN BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 58. SPAIN BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 59. SPAIN BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 60. REST OF EUROPE BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 61. REST OF EUROPE BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 62. REST OF EUROPE BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 63. ASIA-PACIFIC BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 64. ASIA-PACIFIC EWING SARCOMA BONE CANCER TREATMENT MARKET, BY AGE GROUP, 2021-2031 ($MILLION)

TABLE 65. ASIA-PACIFIC BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 66. ASIA-PACIFIC BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 67. ASIA-PACIFIC BONE CANCER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 68. JAPAN BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 69. JAPAN BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 70. JAPAN BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 71. CHINA BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 72. CHINA BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 73. CHINA BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 74. INDIA BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 75. INDIA BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 76. INDIA BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 77. AUSTRALIA BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 78. AUSTRALIA BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 79. AUSTRALIA BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 80. SOUTH KOREA BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 81. SOUTH KOREA BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 82. SOUTH KOREA BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 83. REST OF ASIA-PACIFIC BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 84. REST OF ASIA-PACIFIC BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 85. REST OF ASIA-PACIFIC BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 86. LAMEA BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 87. LAMEA EWING SARCOMA BONE CANCER TREATMENT MARKET, BY AGE GROUP, 2021-2031 ($MILLION)

TABLE 88. LAMEA BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 89. LAMEA BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 90. LAMEA BONE CANCER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 91. BRAZIL BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 92. BRAZIL BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 93. BRAZIL BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 94. SAUDI ARABIA BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 95. SAUDI ARABIA BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 96. SAUDI ARABIA BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 97. SOUTH AFRICA BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 98. SOUTH AFRICA BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 99. SOUTH AFRICA BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 100. REST OF LAMEA BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 101. REST OF LAMEA BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 102. REST OF LAMEA BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 103.ADVAXIS, INC: COMPANY SNAPSHOT

TABLE 104.ADVAXIS, INC: OPERATING SEGMENTS

TABLE 105.ADVAXIS, INC: PRODUCT PORTFOLIO

TABLE 106.ADVAXIS, INC: NET SALES,

TABLE 107.ADVAXIS, INC: KEY STRATERGIES

TABLE 108.TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT

TABLE 109.TAKEDA PHARMACEUTICAL COMPANY LIMITED: OPERATING SEGMENTS

TABLE 110.TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT PORTFOLIO

TABLE 111.TAKEDA PHARMACEUTICAL COMPANY LIMITED: NET SALES,

TABLE 112.TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY STRATERGIES

TABLE 113.CANCERVAX, INC: COMPANY SNAPSHOT

TABLE 114.CANCERVAX, INC: OPERATING SEGMENTS

TABLE 115.CANCERVAX, INC: PRODUCT PORTFOLIO

TABLE 116.CANCERVAX, INC: NET SALES,

TABLE 117.CANCERVAX, INC: KEY STRATERGIES

TABLE 118.CELLECTAR BIOSCIENCES, INC: COMPANY SNAPSHOT

TABLE 119.CELLECTAR BIOSCIENCES, INC: OPERATING SEGMENTS

TABLE 120.CELLECTAR BIOSCIENCES, INC: PRODUCT PORTFOLIO

TABLE 121.CELLECTAR BIOSCIENCES, INC: NET SALES,

TABLE 122.CELLECTAR BIOSCIENCES, INC: KEY STRATERGIES

TABLE 123.PFIZER, INC: COMPANY SNAPSHOT

TABLE 124.PFIZER, INC: OPERATING SEGMENTS

TABLE 125.PFIZER, INC: PRODUCT PORTFOLIO

TABLE 126.PFIZER, INC: NET SALES,

TABLE 127.PFIZER, INC: KEY STRATERGIES

TABLE 128.ISOFOL MEDICAL AB: COMPANY SNAPSHOT

TABLE 129.ISOFOL MEDICAL AB: OPERATING SEGMENTS

TABLE 130.ISOFOL MEDICAL AB: PRODUCT PORTFOLIO

TABLE 131.ISOFOL MEDICAL AB: NET SALES,

TABLE 132.ISOFOL MEDICAL AB: KEY STRATERGIES

TABLE 133.GRADALIS INC: COMPANY SNAPSHOT

TABLE 134.GRADALIS INC: OPERATING SEGMENTS

TABLE 135.GRADALIS INC: PRODUCT PORTFOLIO

TABLE 136.GRADALIS INC: NET SALES,

TABLE 137.GRADALIS INC: KEY STRATERGIES

TABLE 138.HIKMA PHARMACEUTICAL PLC: COMPANY SNAPSHOT

TABLE 139.HIKMA PHARMACEUTICAL PLC: OPERATING SEGMENTS

TABLE 140.HIKMA PHARMACEUTICAL PLC: PRODUCT PORTFOLIO

TABLE 141.HIKMA PHARMACEUTICAL PLC: NET SALES,

TABLE 142.HIKMA PHARMACEUTICAL PLC: KEY STRATERGIES

TABLE 143.QSAM BIOSCIENCES, INC.: COMPANY SNAPSHOT

TABLE 144.QSAM BIOSCIENCES, INC.: OPERATING SEGMENTS

TABLE 145.QSAM BIOSCIENCES, INC.: PRODUCT PORTFOLIO

TABLE 146.QSAM BIOSCIENCES, INC.: NET SALES,

TABLE 147.QSAM BIOSCIENCES, INC.: KEY STRATERGIES

TABLE 148.ZENTALIS PHARMACEUTICALS: COMPANY SNAPSHOT

TABLE 149.ZENTALIS PHARMACEUTICALS: OPERATING SEGMENTS

TABLE 150.ZENTALIS PHARMACEUTICALS: PRODUCT PORTFOLIO

TABLE 151.ZENTALIS PHARMACEUTICALS: NET SALES,

TABLE 152.ZENTALIS PHARMACEUTICALS: KEY STRATERGIES LIST OF FIGURES

FIGURE 1.BONE CANCER TREATMENT MARKET SEGMENTATION

FIGURE 2.BONE CANCER TREATMENT MARKET,2021-2031

FIGURE 3.BONE CANCER TREATMENT MARKET,2021-2031

FIGURE 4. TOP INVESTMENT POCKETS, BY REGION

FIGURE 5.PORTER FIVE-1

FIGURE 6.PORTER FIVE-2

FIGURE 7.PORTER FIVE-3

FIGURE 8.PORTER FIVE-4

FIGURE 9.PORTER FIVE-5

FIGURE 10.TOP PLAYER POSITIONING

FIGURE 11.BONE CANCER TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 12.BONE CANCER TREATMENT MARKET,BY TYPE,2021(%)

FIGURE 13.COMPARATIVE SHARE ANALYSIS OF OSTEOSARCOMA BONE CANCER TREATMENT MARKET,2021-2031(%)

FIGURE 14.COMPARATIVE SHARE ANALYSIS OF CHONDROSARCOMA BONE CANCER TREATMENT MARKET,2021-2031(%)

FIGURE 15.COMPARATIVE SHARE ANALYSIS OF EWING SARCOMA BONE CANCER TREATMENT MARKET,2021-2031(%)

FIGURE 16.COMPARATIVE SHARE ANALYSIS OF OTHERS BONE CANCER TREATMENT MARKET,2021-2031(%)

FIGURE 17.BONE CANCER TREATMENT MARKET,BY DRUG TYPE,2021(%)

FIGURE 18.COMPARATIVE SHARE ANALYSIS OF IMMUNOTHERAPY AND TARGETED THERAPY BONE CANCER TREATMENT MARKET,2021-2031(%)

FIGURE 19.COMPARATIVE SHARE ANALYSIS OF CHEMOTHERAPY BONE CANCER TREATMENT MARKET,2021-2031(%)

FIGURE 20.BONE CANCER TREATMENT MARKET,BY DISTRIBUTION CHANNEL,2021(%)

FIGURE 21.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACIES BONE CANCER TREATMENT MARKET,2021-2031(%)

FIGURE 22.COMPARATIVE SHARE ANALYSIS OF DRUG STORE AND RETAIL PHARMACIES BONE CANCER TREATMENT MARKET,2021-2031(%)

FIGURE 23.COMPARATIVE SHARE ANALYSIS OF ONLINE PHARMACIES BONE CANCER TREATMENT MARKET,2021-2031(%)

FIGURE 24.BONE CANCER TREATMENT MARKET BY REGION,2021

FIGURE 25.U.S. BONE CANCER TREATMENT MARKET,2021-2031($MILLION)

FIGURE 26.CANADA BONE CANCER TREATMENT MARKET,2021-2031($MILLION)

FIGURE 27.MEXICO BONE CANCER TREATMENT MARKET,2021-2031($MILLION)

FIGURE 28.GERMANY BONE CANCER TREATMENT MARKET,2021-2031($MILLION)

FIGURE 29.FRANCE BONE CANCER TREATMENT MARKET,2021-2031($MILLION)

FIGURE 30.UK BONE CANCER TREATMENT MARKET,2021-2031($MILLION)

FIGURE 31.ITALY BONE CANCER TREATMENT MARKET,2021-2031($MILLION)

FIGURE 32.SPAIN BONE CANCER TREATMENT MARKET,2021-2031($MILLION)

FIGURE 33.REST OF EUROPE BONE CANCER TREATMENT MARKET,2021-2031($MILLION)

FIGURE 34.JAPAN BONE CANCER TREATMENT MARKET,2021-2031($MILLION)

FIGURE 35.CHINA BONE CANCER TREATMENT MARKET,2021-2031($MILLION)

FIGURE 36.INDIA BONE CANCER TREATMENT MARKET,2021-2031($MILLION)

FIGURE 37.AUSTRALIA BONE CANCER TREATMENT MARKET,2021-2031($MILLION)

FIGURE 38.SOUTH KOREA BONE CANCER TREATMENT MARKET,2021-2031($MILLION)

FIGURE 39.REST OF ASIA-PACIFIC BONE CANCER TREATMENT MARKET,2021-2031($MILLION)

FIGURE 40.BRAZIL BONE CANCER TREATMENT MARKET,2021-2031($MILLION)

FIGURE 41.SAUDI ARABIA BONE CANCER TREATMENT MARKET,2021-2031($MILLION)

FIGURE 42.SOUTH AFRICA BONE CANCER TREATMENT MARKET,2021-2031($MILLION)

FIGURE 43.REST OF LAMEA BONE CANCER TREATMENT MARKET,2021-2031($MILLION)

FIGURE 44. TOP WINNING STRATEGIES, BY YEAR

FIGURE 45. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 46. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 47.PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 48.COMPETITIVE DASHBOARD

FIGURE 49.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS

FIGURE 50.ADVAXIS, INC.: NET SALES ,($MILLION)

FIGURE 51.TAKEDA PHARMACEUTICAL COMPANY LIMITED.: NET SALES ,($MILLION)

FIGURE 52.CANCERVAX, INC.: NET SALES ,($MILLION)

FIGURE 53.CELLECTAR BIOSCIENCES, INC.: NET SALES ,($MILLION)

FIGURE 54.PFIZER, INC.: NET SALES ,($MILLION)

FIGURE 55.ISOFOL MEDICAL AB.: NET SALES ,($MILLION)

FIGURE 56.GRADALIS INC.: NET SALES ,($MILLION)

FIGURE 57.HIKMA PHARMACEUTICAL PLC.: NET SALES ,($MILLION)

FIGURE 58.QSAM BIOSCIENCES, INC..: NET SALES ,($MILLION)

FIGURE 59.ZENTALIS PHARMACEUTICALS.: NET SALES ,($MILLION